N@N

Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen

_{//health-fitness.news-articles.net/content/2013/ .. -sale-of-equity-interest-in-shanghai-celgen.html}
^{Published in Health and Fitness on Tuesday, January 22nd 2013 at 3:00 GMT by Market Wire}  

Simcere Pharmaceutical Group Announces Sale of Equity Interest in Shanghai Celgen -- NANJING, China, Jan. 22, 2013 /PRNewswire/ --

NANJING, China, Jan. 22, 2013 /PRNewswire/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: [ SCR ]), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that the Company entered into a share transfer agreement with Devont Asset Management Limited on January 15^th 2013 to sell an approximately 35% equity interest in Shanghai Celgen Bio-Pharmaceutical Co., Ltd. ("Shanghai Celgen") for a cash consideration of RMB 302 million. Simcere indirectly acquired an approximately 35% equity interest in Shanghai Celgen in August 2009. Upon completion of this transaction, Simcere will no longer hold any equity interest in Shanghai Celgen. Consummation of the transaction is subject to certain closing conditions.  

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: [ SCR ]) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit [ www.simcere.com ].

Investor and Media Contacts:

Email: [ ir@simcere.com ]

SOURCE Simcere Pharmaceutical Group